Can a diabetes drug also protect the heart? new study tests liraglutide
NCT ID NCT04866667
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study screened 316 people with type 2 diabetes who were at high risk for heart disease. Researchers tested whether adding the drug liraglutide to standard care could reduce new heart problems like heart attacks, strokes, and hospitalizations. The goal was to see if this approach could better control blood sugar, cholesterol, and blood pressure while preventing cardiovascular events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liraglutide (a GLP-1 receptor agonist drug)
What this could lead to
If successful, this could show that liraglutide helps prevent heart attacks, strokes, and other cardiovascular problems in people with type 2 diabetes.
What could go wrong
This is a completed study with 316 participants, but results are not yet widely reported. The benefit may be modest and not apply to all diabetes patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang provincial people's hospital
Hangzhou, Zhejiang, 310014, China